Artículos de revistas sobre el tema "A-510"
Siga este enlace para ver otros tipos de publicaciones sobre el tema: A-510.
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "A-510".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
1
Michael Sharp, Stewart. "What‘s a 510(K)?" MOJ Clinical & Medical Case Reports 8, n.º 6 (2018): 241. http://dx.doi.org/10.15406/mojcr.2018.08.00288.
Texto completo
2
Sakamoto Martini, Gessica, Jeremy Kendal y Jamshid Johari Tehrani. "Cinderella’s Family Tree. A Phylomemetic Case Study of ATU 510/511". Fabula 64, n.º 1-2 (1 de julio de 2023): 7–30. http://dx.doi.org/10.1515/fabula-2023-0002.
Texto completoResumen
Abstract This case study contributes to recent attempts to apply “phylomemetic” methods derived from computational biology to oral traditions, where the aim is to trace the mutation and diversification of folk narratives as they get passed on from generation to generation and spread from society to society. Our study focuses on one of the most famous and widespread tales in the folktale record: Cinderella. Thousands of Cinderella-like stories have been documented from around the world, which folklorists have attempted to classify into different “types” representing distinct, though related, international traditions. The most comprehensive of Cinderella typologies was developed by Anna Birgitta Rooth (1951), who divided the tales into five principal types: A, B, AB, BI and C, and suggested several hypotheses pertaining to their origins and relationships to one another. Here, we test Rooth’s theories on a sample of 266 versions of Cinderella using Bayesian phylogenetic inference, phylogenetic networks (NeighborNet) and a model-based clustering method that was originally designed to elicit population structure from multi-locus genotype data (implemented in the program STRUCTURE). Our results find varying levels of support for the types identified by Rooth, and suggest that mixing among traditions was widespread, especially in Type AB tales. Despite these complexities, it was still possible to delineate and quantify the influence of distinct ancestral sources on the variation observed in contemporary versions of Cinderella. Our study highlights the value and versatility of phylomemetic methods in uncovering the historical relationships among types and sub-types of international folktale, as well as the evolutionary processes that have shaped them.
3
Munzner, R. "What's in a 510(k)?" IEEE Engineering in Medicine and Biology Magazine 22, n.º 3 (mayo de 2003): 157–58. http://dx.doi.org/10.1109/memb.2003.1213643.
Texto completo
4
Surikov, I. E. "On Athens` Coinage at the End of the Archaic Period (A Historical Context of Transition from Wappenmünzen to “Owls”)". Ancient World and Archaeology 19 (18 de diciembre de 2019): 12–18. http://dx.doi.org/10.18500/0320-961x-2019-19-12-18.
Texto completoResumen
The article deals with the fate of the first Athenian coinage (coins known under the conventional name of Wappenmünzen) at its latest stage, when there took place a transition to coins of principally new type (“head of Athena – owl”, ΑΘΕ), which later became so glorious. The author connects the transition mentioned with the fall of tyranny in 510 BC and dates a little earlier beginning of Wappenmünzen tetradrachms issuing to 514–513 BC, while correlating it with such events as the tyrants Hippias’ clash with aristocrats and hardening of his policies. In the same context he tries to interpret the so-called Hippias’ monetary reform, which is mentioned vaguely in Pseudo-Aristotle’s Economics.
5
Wu, Wei, Linyan He, Yan Huang, Likun Hou, Wei Zhang, Liping Zhang y Chunyan Wu. "MicroRNA-510 Plays Oncogenic Roles in Non-Small Cell Lung Cancer by Directly Targeting SRC Kinase Signaling Inhibitor 1". Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 27, n.º 8 (8 de agosto de 2019): 879–87. http://dx.doi.org/10.3727/096504018x15451308507747.
Texto completoResumen
An increasing number of studies have demonstrated that microRNAs (miRNAs) may play key roles in various cancer carcinogenesis and progression, including non-small cell lung cancer (NSCLC). However, the expressions, roles, and mechanisms of miR-510 in NSCLC have, up to now, been largely undefined. In vivo assay showed that miR-510 was upregulated in NSCLC tissues compared with that in adjacent nontumor lung tissues. miR-510 expression was significantly correlated with TNM stage and lymph node metastasis. In vitro assay indicated that expressions of miR-510 were also increased in NSCLC cell lines. Downregulation of miR-510 suppressed NSCLC cell proliferation and invasion in vitro. We identified SRC kinase signaling inhibitor 1 (SRCIN1) as a direct target gene of miR-510 in NSCLC. Expression of SRCIN1 was downregulated in lung cancer cells and negatively correlated with miR-510 expression in tumor tissues. Downregulation of SRCIN1, leading to inhibition of miR-510 expression, reversed cell proliferation and invasion in NSCLC cells. These results showed that miR-510 acted as an oncogenic miRNA in NSCLC, partly by targeting SRCIN1, suggesting that miR-510 can be a potential approach for the treatment of patients with malignant lung cancer.
6
Uronis, H. E., J. Bendell, G. Blobe, M. Morse, D. Geier, A. Nixon, L. Howard, D. Evans, H. Li y H. Hurwitz. "A phase I study of bevacizumab (BV) plus ABT-510 in patients with advanced solid tumors". Journal of Clinical Oncology 25, n.º 18_suppl (20 de junio de 2007): 3541. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.3541.
Texto completoResumen
3541 Background: BV is a potent inhibitor of vascular endothelial growth factor (VEGF) with broad clinical activity both alone and in combination. ABT-510 is a 9 amino acid synthetic analog of the N-terminal region of thrombospondin (TSP-1), an endogenous inhibitor of angiogenesis. ABT-510 exhibits anti-angiogenic effects in preclinical models and has been well-tolerated as a single agent in previous Phase I & 2 studies. As a combination anti-angiogenesis therapy, we evaluated BV + ABT-510 in a phase I biomarker study. Methods: In cohorts of 3–6 patients, BV and ABT-510 were evaluated. BV was dosed in mg/kg IV q2weeks and ABT-510 was given daily in mg SC BID; cycle length was 28 days. Dose levels were as follows: (1) BV 5/ ABT-510 50; (2) BV 10/ ABT-510 50; (3) BV 10/ ABT-510 100. At the recommended phase II dose, 20 patients are being enrolled for detailed biomarker studies. DLT was defined as any hematological toxicity = grade 4 or grade = 3 non- hematological event in Cycle 1 related to treatment, with the exception of grade 3 hypertension adequately controlled by medication. Eligible patients had advanced solid tumors, adequate organ and marrow function, and no co-morbidities suggesting increased risk for class-related toxicities. Dermal wound angiogenesis assays were analyzed for visualization as well as phospho-VEGFR2, TGFβ, phospho-AKT, and thrombospondin-1 and -2, both pre- and on-treatment. Plasma was assayed for multiple angiogenic factors. Results: 22 patients have been enrolled; 17 are currently evaluable for toxicity and 14 for efficacy. No DLT were seen in any cohort. Possible treatment related adverse events occurring in later cycles included: gr3 GI bleed (n=1) and gr3 headache (n=1). 7 patients had stable disease as best response (range 8- 64+ weeks); 2 remain on therapy, one at 64+ weeks and one at 24+ weeks. Conclusions: BV + ABT-510 is well-tolerated and has hints of activity in refractory tumors. The recommended phase II dose is BV 10mg/kg IV q14d and ABT-510 100mg SC BID. Updated clinical and biomarker data will be presented. No significant financial relationships to disclose.
7
Vasquez-Pinto, L. M., A. K. Silva, J. R. Nicoli, D. D. Rodriguez y F. S. Martins. "510 A novel anti-ageing probiotic technology". Journal of Investigative Dermatology 136, n.º 5 (mayo de 2016): S90. http://dx.doi.org/10.1016/j.jid.2016.02.547.
Texto completo
8
Hang, Junjie, Feifei Wei, Zhiying Yan, Xianming Zhang, Kequn Xu y Yingwei Zhu. "The value of miR-510 in the prognosis and development of colon cancer". Open Medicine 16, n.º 1 (1 de enero de 2021): 795–804. http://dx.doi.org/10.1515/med-2021-0251.
Texto completoResumen
Abstract Purpose Colon cancer is one of the malignant tumors that threatens human health. miR-510 was demonstrated to play roles in the progression of various cancers; its dysregulation was speculated to be associated with the development of colon cancer. Methods One hundred and thirteen colon cancer patients participated in this research. With the help of RT-qPCR, the expression of miR-510 in collected tissues and cultured cells was analyzed. The association between miR-510 expression level and clinical features and prognosis of patients was evaluated. Moreover, the effects of miR-510 on cell proliferation, migration, and invasion of colon cancer were assessed by CCK8 and Transwell assay. Results miR-510 significantly upregulated in colon cancer tissues and cell lines relative to the adjacent normal tissues and colonic cells. The expression of miR-510 was significantly associated with the TNM stage and poor prognosis of patients, indicating miR-510 was involved in the disease progression and clinical prognosis of colon cancer. Additionally, the upregulation of miR-510 significantly promoted cell proliferation, migration, and invasion of colon cancer, while its knockdown significantly inhibited these cellular processes. SRCIN 1 was the direct target of miR-510 during its promoted effect on the development of colon cancer. Conclusion The upregulation of miR-510 acts as an independent prognostic indicator and a tumor promoter by targeting SRCIN 1 in colon cancer, which provides novel therapeutic strategies for colon cancer.
9
Joyce, D. E., G. Mulji, L. S. Gutierrez y F. J. Castellino. "Evaluation of the thrombospondin-1 analogue ABT-510 in the APCMin/+ mouse intestinal adenoma model". Journal of Clinical Oncology 24, n.º 18_suppl (20 de junio de 2006): 13545. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.13545.
Texto completoResumen
13545 Background: The extracellular matrix protein Thrombospondin-1 (TSP-1) affects the angiogenic balance in cancer to suppress tumor growth. Exogenous TSP-1 or the peptide derivative ABT-510 (Abbott, Chicago, IL) can reverse this angiogenic switch from adenoma to carcinoma. We evaluated treatment effects of ABT-510 in the APCMin/+ mouse spontaneous intestinal adenoma model. This study determined reduction in intestinal adenoma number after ABT-510 or the combined treatment of ABT-510/bevacizumab (Genentech) compared to no treatment in APCMin/+. Proliferation, vascularity, and dysplasia were also compared. Methods: 90 day old APCMin/+ mice (familial adenomatous polyposis, 5q21 termination), Jackson Laboratory (Bar Harbor, ME)) received drug for three weeks: 1.) ABT-510, 60 mg/Kg/day s.c. pump for 2 weeks then i.p. daily for the last 7 days, 2.) Anti-VEGF antibody bevacizumab 10 mg/Kg i.p. twice per week in combination with ABT-510, and 3.) untreated controls. After 21 days mice were sacrificed, intestines harvested and adenomas enumerated. Immunohistochemistry (PCNA, vWF/CD31) was performed. Studies were IACUC approved. Wilcoxon signed-rank test was used to compare results. Results: Twenty one mice were evaluated with no adverse effects. Comparisons were made to untreated APCMin/+ controls. Untreated controls (N=7) demonstrated a mean of 7.7±1.25 polyps. ABT-510 treated APCMin/+ (N=8) demonstrated a mean of 3.4±1.8 polyps, significantly different from controls (p<0.004). Combined bevacizumab and ABT-510 treatment demonstrated a mean of 4.7 ±3.0 polyps (p<0.008). There was no significant difference between the ABT-510 and combined ABT-510/bevacizumab treated groups. Immunohistochemistry for tumor vascularity (anti-CD31/anti-vWF) and for proliferation (PCNA) demonstrated enhanced vascular and PCNA staining in polyps, but no differences were detected in tumor dysplasia or immunohistochemistry compared across control and treatment groups. Conclusions: Significant reduction in APCMin/+ polyp number was seen with ABT-510 and the combination ABT-510/bevacizumab treatment groups compared to untreated controls. Tumor-specific vascularity and proliferation was characteristically no different across control and treated groups. [Table: see text]
10
Fakih, Marwan, Greg Andrew Durm, Ramaswamy Govindan, Gerald Steven Falchook, Neelesh Soman, Haby Adel Henary y David S. Hong. "Trial in progress: A phase Ib study of AMG 510, a specific and irreversible KRASG12C inhibitor, in combination with other anticancer therapies in patients with advanced solid tumors harboring KRAS p.G12C mutation (CodeBreak 101)." Journal of Clinical Oncology 38, n.º 15_suppl (20 de mayo de 2020): TPS3661. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.tps3661.
Texto completoResumen
TPS3661 Background: Kirsten rat sarcoma viral oncogene homolog (KRAS) p.G12C mutation has been identified as a driver oncogenic mutation in several solid tumors (eg, non-small cell lung cancer [NSCLC], colorectal cancer [CRC]). Development of therapies targeting KRASG12C has been unsuccessful. AMG 510 is a specific and irreversible small molecule inhibitor of KRASG12C. A first-in-human clinical trial of AMG 510 monotherapy in patients with KRAS p.G12C mutant solid tumors is currently ongoing. AMG 510 in combination with additional anticancer therapies may lead to enhanced antitumor efficacy. This study is a master protocol designed to evaluate multiple investigational regimens of AMG 510 in patients with KRAS p.G12C mutant solid tumors. Here, we present two combination cohorts of AMG 510 with a mitogen-activated protein kinase kinase (MEK) inhibitor and an investigational anti-programmed cell death protein-1 (PD-1) therapy, respectively. Additional combination cohorts will be presented at the meeting. Methods: This is a phase 1b, open-label study evaluating AMG 510 in combination with a MEK inhibitor or an investigational anti-PD-1 therapy in pts with KRAS p.G12C mutant solid tumors. The dose exploration phase (part 1; n=20) will evaluate the safety and tolerability of AMG 510 in combination with the MEK inhibitor or anti-PD-1 therapy; this will be followed by a dose expansion phase (part 2; n=40) to verify the safety and tolerability profile of AMG 510 combination therapies and assess antitumor efficacy. Key eligibility criteria include locally-advanced or metastatic malignancy with KRAS p.G12C mutation identified through molecular testing and at least one or multiple lines of prior systemic therapy (eg, ≥2 for advanced/metastatic colorectal cancer). Primary endpoints include dose-limiting toxicities, treatment-emergent or -related adverse events. Secondary endpoints include pharmacokinetic parameters of combination regimens, disease control rate, duration of response, progression-free survival, and duration of stable disease (measured by computed tomography or magnetic resonance imaging and assessed per RECIST 1.1). The study began enrolling pts in December 2019 and is ongoing. For more information, please contact Amgen Medical Information: medinfo@amgen.com . Clinical trial information: NCT04185883 .
11
Cikojevic, Anica y Eunice S. Wang. "Preclinical Anti-Tumor Efficacy of ABT-510 (Thrombospondin-1 Mimetic Peptide), a Novel Anti-Angiogenic Agent, in Hematological Malignancies." Blood 106, n.º 11 (16 de noviembre de 2005): 2423. http://dx.doi.org/10.1182/blood.v106.11.2423.2423.
Texto completoResumen
Abstract Thrombospondin-1 (TSP-1) is a multi-functional 420 kDa matrix protein implicated in cancer cell adhesion, migration, and invasion and is a potent anti-angiogenic agent. TSP-1 expression is inversely correlated with vascularization and malignant progression of breast and lung cancers but has not been extensively investigated in hematological malignancies. We found low total mRNA levels of TSP-1 expression by RT-PCR in half (7 out of 14) of human cell lines representing lymphoma, leukemia, and myeloma. We also found lower total mRNA TSP-1 levels in two thirds (10 out of 15) of primary patient leukemia samples as compared to human umbilical vein endothelial cells (HUVEC). Treatment of human leukemia and lymphoma cell lines with recombinant TSP-1 (100 mg/ml) or ABT-510 (a novel synthetic peptide derivative of TSP-1) decreased tumor cell proliferation as measured by tritiated thymidine incorporation. Single agent ABT-510 treatment (total daily doses 50–120 mg/kg i.p. daily) resulted in statistically significant reduction in tumor volumes of subcutaneous SKI-DLBCL (diffuse large B cell lymphoma) xenografts. ABT-510 treatment (60 mg/kg IP bid) in disseminated SKI-DLBCL lymphoma mouse models resulted in increased long-term survival consistent with delayed disease progression. We then examined the effects of ABT-510 treatment in combination with anthracycline chemotherapy used in standard lymphoma regimens (doxorubicin) or another anti-angiogenic agent (anti-hVEGF antibody Avastin) in subcutaneous lymphoma xenografts. Our results suggest an additive effect with concomitant ABT-510 (60 mg/kg bid) and doxorubicin (3 mg/kg TIW) treatment, but no additive effect with concomitant ABT-510 (60 mg/kg bid) and Avastin (3 mg/kg TIW) treatment. Conclusion: Our data suggest that decreased levels of thrombospondin-1, a matrix protein with endogenous anti-angiogenic activity, play a role in the growth of human hematological malignancies. Based on these results, the TSP-1 synthetic peptide, ABT-510, represents a novel anti-angiogenic therapeutic strategy for patients with these diseases and warrants additional preclinical investigation in combination regimens. (Of note, a phase II trial of single agent ABT-510 in refractory/relapsed lymphoma patients has recently completed enrollment).
12
Liebeskind, Alexander Y., Amanda C. Chen, Sanket S. Dhruva y Art Sedrakyan. "A 510(k) ancestry of robotic surgical systems". International Journal of Surgery 98 (febrero de 2022): 106229. http://dx.doi.org/10.1016/j.ijsu.2022.106229.
Texto completo
13
Cheung, Jim W. y Bruce B. Lerman. "CVT-510: A Selective A1 Adenosine Receptor Agonist". Cardiovascular Drug Reviews 21, n.º 4 (7 de junio de 2006): 277–92. http://dx.doi.org/10.1111/j.1527-3466.2003.tb00122.x.
Texto completo
14
Thorpe, L. y E. Tamura. "A New 510-Element CCD Camcorder for ENG". SMPTE Journal 96, n.º 6 (junio de 1987): 518–26. http://dx.doi.org/10.5594/j03137.
Texto completo
15
Telichko, Olga, Elena Lastushkina, Oksana Syrmolot, Tatiana Belova, Yuliya Samagina y Polina Bogdan. "Evaluating corn for resistance to the main fungal pathogens and the Asian corn borer". E3S Web of Conferences 510 (2024): 01001. http://dx.doi.org/10.1051/e3sconf/202451001001.
Texto completoResumen
The paper presents the results of a study on 36 corn genotypes of Russian and foreign breeding origin under the conditions of the south of the Russian Far East. The research goal was to select corn varieties (hybrids) with the highest resistance to fungal pathogens and Ostrinia furnacalis Guenee for further use as breeding material. Diseases and pests cause significant damage to corn under the conditions of Primorsky kray. The research identified the following specimens that had the highest tolerance (the frequency of occurrence did not exceed 45%; the degree of disease progression was below 10%) to northern corn leaf blight (Helminthosporium turcicum Pass) and Fusarium ear rot (Fusarium moniliforme Scheldon): Krasnodarsky 291, LONG KEN 134, LONG KEN 1108, LONG KEN 1110, and KENDGY 717. Ostrinia furnacalis Guenee caused little damage (the degree of damage was 0.2-0.5) to Mashuk 175, Mashuk 250, Mashuk 300, N’yuton, KENDGY 717, DEMEYA 4, KENDGY 515, KENDGY 510, and LONG KEN 1110. High yield (7.2-8.8 t/ha) characterized Mashuk 250, N’yuton, Stella, KENDGY 717, KENDGY 510, DEMEYA 4, KENDGY 515, LONG KEN 134, and LONG KEN 1110.
16
Langermans, J. A., M. E. van der Hulst, P. H. Nibbering y R. van Furth. "Activation of mouse peritoneal macrophages during infection with Salmonella typhimurium does not result in enhanced intracellular killing." Journal of Immunology 144, n.º 11 (1 de junio de 1990): 4340–46. http://dx.doi.org/10.4049/jimmunol.144.11.4340.
Texto completoResumen
Abstract Our study was performed to investigate whether macrophages become activated during an infection with Salmonella typhimurium and, if so, whether these activated macrophages kill S. typhimurium faster than resident macrophages. Mice received i.v. injections with a sublethal number of S. typhimurium; on about day 12 of the infection the numbers of bacteria in the liver and the spleen were maximal. During the infection, activation of peritoneal macrophages could be demonstrated on the basis of three criteria, i.e., the ability to inhibit the proliferation of Toxoplasma gondii, an enhanced production of H2O2 and an increased expression of Ia Ag. The rate of in vitro intracellular killing of S. typhimurium by these activated macrophages was not increased compared to that for resident macrophages. To determine the growth of S. typhimurium in activated mice a nalidixic acid-resistant mutant strain, called S. typhimurium 510R, was used. The net growth rates of the mutant S. typhimurium 510R in the spleen of S. typhimurium 510-activated and normal mice were similar. However, in the liver of S. typhimurium 510-activated mice the number of S. typhimurium 510R did not change during 3 to 48 h after injection. The role of specific antibodies during the initial phase of the infection was negligible, because only low levels of antibodies were detected during the first 15 days of infection and the growth rates of S. typhimurium 510 in the spleen and liver of mice with high titers of antibodies were not significantly different from the rates in normal mice. The results of this study demonstrate that although macrophages become activated during an infection with S. typhimurium, these cells do not display an enhanced bactericidal activity in vitro and in vivo no significant effect on the growth rate of S. typhimurium in the spleen and a bacteriostatic effect in the liver is found. Hence macrophage activation is probably not very important in the host defense against S. typhimurium.
17
Sun, Jijian, Shijie Pan, Hongquan Cui y Hao Li. "CircRNA SCARB1 Promotes Renal Cell Carcinoma Progression Via Mir- 510-5p/SDC3 Axis". Current Cancer Drug Targets 20, n.º 6 (7 de julio de 2020): 461–70. http://dx.doi.org/10.2174/1568009620666200409130032.
Texto completoResumen
Background: Emerging studies have indicated that circular RNAs (circRNAs) play important roles in the development of many tumors. CircRNA-scavenger receptor class B member 1 (Circ-SCARB1) was consistently reported as an elevated circRNA in RCC tissues. This study focused on examining the biological function and molecular mechanism of circSCARB1 in RCC progression. Methods: Expressions of Circ-SCARB1, microRNA (miR)-510-5p, and syndecan 3 (SDC3) were detected using a quantitative real-time polymerase chain reaction (RT-PCR) and/or western blot. Cell proliferation and apoptosis were measured by 3-(4, 5)-dimethylthiahiazo (-z-y1)-3, 5-diphenytetrazoliumromide and flow cytometry, respectively. Cell migration and invasion were measured using Transwell assays. The interaction between miR-510-5p and Circ-SCARB1 or SDC3 was verified using dual-luciferase reporter assays. Results: Circ-SCARB1 was elevated in 30 pairs of RCC tissues and multiple RCC cell lines. Knockdown of Circ-SCARB1 inhibited cell proliferation, migration, and invasion while inducing cell apoptosis. MiR-510-5p was confirmed to be a target of Circ-SCARB1; inhibition of cell progression by silencing Circ-SCARB1 was mediated by a direct interaction between Circ-SCARB1 and miR-510-5p. SDC3 was verified to be a gene target of miR-510-5p; transfection of miR-510-5p mimic not only suppressed the expression of SDC3 but also the cell proliferation and an SDC3 cotransfection partially restored cell proliferation. Additionally, the genetic knockdown of Circ- SCARB1 reduced the expression SDC3, and the addition of anti-miR-510-5p could partially reelevate SDC3 expression. Conclusion: Circ-SCARB1 promotes RCC progression via sequestering miR-510-5p and indirectly up-regulating SDC3 expression. This provides a novel perspective for the pathogenesis of RCC and potential therapeutic targets for the treatment of RCC.
18
Ferreira, Rodrigo. "O “platonismo” matemático de Platão". Griot : Revista de Filosofia 23, n.º 3 (31 de octubre de 2023): 1–10. http://dx.doi.org/10.31977/grirfi.v23i3.3411.
Texto completoResumen
Diversos filósofos e matemáticos contemporâneos admitem que existe uma vertente da filosofia matemática denominada “Platonismo”, segundo a qual, em síntese, os entes matemáticos – números, pontos, retas, planos, etc. – são coisas que existem no mundo independentemente de nós. Na literatura especializada é recorrente a compreensão de que essa tese filosófica tem origem na teoria das formas de Platão. Entretanto, a assertiva de que os entes matemáticos existem em si mesmos não é encontrada na filosofia desse filósofo ateniense, observada a passagem 509d, e seguintes, do seu diálogo A República. Na verdade, segundo o pensamento matemático de Platão os entes matemáticos possuem um valor intermediário, como mostramos nas seções a seguir ao “reconstruirmos” o seu raciocínio da “linha dividida”, segundo os trechos da República: (1) Livro V: 477a-b, 477e, 478b, 478c, 478d; (2) Livro VI: 509d-e, 510a, 510b, 510c-d, 510e, 511a, 511 a-b, 511d, 511e; (3) Livro VII: 533 b-c, 534a.
19
Camden, Marie-Christine, Michael D. Hill, Andrew M. Demchuk, Alexandre Y. Poppe, Nan Shobha, Philip A. Barber y Shelagh B. Coutts. "Historic Stroke Motor Severity Score Predicts Progression in TIA/Minor Stroke". Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 41, n.º 1 (enero de 2014): 19–23. http://dx.doi.org/10.1017/s0317167100016206.
Texto completoResumen
Background:transient ischemic attack (tIA) and minor stroke have a high risk of early neurological deterioration, and patients who experience early improvement are at risk of deterioration. We generated a score for quantifying the worst reported motor and speech deficits and assessed whether this predicted outcome.Methods:510 tIA or minor stroke (NIHSS>4) patients were included. the Historical Stroke Severity Score (HSSS) prospectively quantified the patient's description of the worst motor or speech deficits. the HSSS was rated at the time of first assessment with more severe deficits scoring higher. Motor HSSS included assessments of arm and leg motor power (score total 0-5). Speech HSSS assessed severity of dysarthria and aphasia (total 0-3). the association between motor and speech HSSS and symptom progression was assessed during the 90-day follow-up period.Results:the proportion of patients in each category of the motor HSSS was 0: 43% (216/510), 1: 22%(110/510), 2: 17% (89/510), 3: 7% (37/510), 4: 5% (28/510) and 5: 6% (30/510). Motor HSSS was associated with symptom progression (p=0.004) but not recurrent stroke. Speech HSSS was not associated with either progression or recurrent stroke. Motor HSSS predicted disability (p=0.002) and intracranial occlusion (p=0.012). Disability increased with increasing motor HSSS.Conclusions:taking a detailed history about the severity of motor deficits, but not speech, predicted outcome in tIA and minor stroke patients. A score based on the patient's description of the severity of motor symptoms predicted symptom progression, intracranial occlusion and functional outcome, but not recurrent stroke in a tIA and minor stroke population.
20
Yang, Yaqin, Chongli Mu, Zhongjian Han, Jian Xu y Baocheng Li. "Analysis of the In Situ Crack Evolution Behavior in a Solid Solution Mg-13Gd-5Y-3Zn-0.3Zr Alloy". Materials 14, n.º 1 (24 de diciembre de 2020): 36. http://dx.doi.org/10.3390/ma14010036.
Texto completoResumen
The low plasticity of high strength Mg-Gd-Y alloy has become the main obstacle to its application in engineering. In this paper, the origin, propagation and fracture processes of cracks of a solution of treated Mg-13Gd-5Y-3Zn-0.3Zr alloy were observed and studied with scanning electron microscopy (SEM) in an in situ tensile test to provide theoretical references for the development of a new high-performance Mg-Gd-Y alloy. The results showed that there was still some bulk long period stacking order (LPSO) phase remaining in solid solution Mg-13Gd-5Y-3Zn-0.3Zr alloy. Most importantly, it was found that the locations of micro-cracks vary with the different solution treatment processes, mainly including the following three types. (1) At 480 × 10 h and 510 °C × 10 h, much bulk LPSO phase with higher elastic modulus remains in the alloy, which can lead to micro-cracks in the LPSO phase due to stress concentration. (2) At 510 °C × 13 h and 510 °C × 16 h, the phase structure of bulk LPSO changes, and the stress concentration easily appears at the LPSO/α-Mg interface, which leads to micro-cracks at the interface. (3) At 510 °C × 19 h and 510 °C × 22 h, the grain size increases, and the stress concentration is obvious at the grain boundary of coarse grains, which leads to the formation of micro-cracks.
21
Munzner, R. "Regulatory issues - Marketing a medical device without a 510(k)". IEEE Engineering in Medicine and Biology Magazine 22, n.º 5 (septiembre de 2003): 133. http://dx.doi.org/10.1109/memb.2003.1256287.
Texto completo
22
ДОБРОВОЛЬСКАЯ, В. Е. "The plot type ATU 510B “Peau d’Asne” (SUS 510B “Pigskin Cover”) in the Russian fairytale tradition". ТРАДИЦИОННАЯ КУЛЬТУРА, n.º 1 (25 de marzo de 2019): 20–30. http://dx.doi.org/10.26158/tk.2019.20.1.002.
Texto completoResumen
В статье рассматриваются русские волшебные сказки сюжетного типа 510В. Среди двадцати отмеченных в указателе СУС текстов к сюжетному типу 510В принадлежат лишь пять. В результате анализа текстов в научный оборот введены еще четыре текста сюжетного типа 510В и выявлены тексты, относящиеся к группе -510В*. В статье показано, что в русской сказочной традиции сказки сюжетного типа 510В довольно редко представлены как самостоятельный сюжетный тип. Существенно чаще они представляют собой контаминацию нескольких типов, например, 313Е*, 510А, -510В*, 403 и 480. Такое объединение связано с несколькими при- чинами. Данный сюжетный тип не относится к ядру волшебной сказки; он не самый популярный и, следовательно, его каноническая структура нестабильна. Он близок по сюжетной коллизии к сказкам, в которых отец или брат хочет жениться на доче- ри или сестре, что позволяет сказочникам использовать мотивы сюжетно близких типов (313Е*, -510В*). Сказки данного типа относятся к группе текстов о невинно гонимых, что дает возможность сказочникам использовать как мотивы из сюжетных типов, связанных с невинно гонимой девушкой или женщиной (403), так и те, где в роли жертвы выступает падчерица (480 и 510А). The article deals with Russian fairytales of the plot type 510B. Among the twenty texts noted in the SUS index, only five texts really belong to this type. Analysis reveals four new texts to be of the plot type 510В and brings to light another group of texts belonging to the group -510В*. The article shows that in the Russian fairytale tradition, fairytales of the plot type 510B are rarely discussed as an independent plot type. Much more often they are seen as a contamination of 510B with other types, for example 313Е*, 510А, -510В*, 403, and 480. There are several reasons for this. The plot type 510B does not belong to the core of the fairytale tradition; it is not among the most popular and therefore its canonical structure is unstable. In addition, its plot is close to other tales in which a father or brother wants to marry a daughter or sister; this allows storytellers to use motifs from analogous plot types (313Е*, -510В*). In addition, tales of type 510B belong to the group of texts about persecuted innocents, which allows storytellers to use motifs from plot types associated with an unjustly persecuted girl or woman (403) and from those where the victim is the stepdaughter (480 and 510A).
23
Zhang, Rong, Amy Riek y Cynthia Herrick. "Abstract #510 Pheochromocytoma in Kidney Disease: A Case Series". Endocrine Practice 25 (abril de 2019): 253–54. http://dx.doi.org/10.1016/s1530-891x(20)46854-5.
Texto completo
24
NAMBARA, Yoshitaka, Eizi KATO y Tutomu TATIKAWA. "510 Flow around a Savonius rotor in accelerated flow". Proceedings of Ibaraki District Conference 2006 (2006): 121–22. http://dx.doi.org/10.1299/jsmeibaraki.2006.121.
Texto completo
25
Everhart, Alexander O., Soumya Sen, Ariel D. Stern, Yi Zhu y Pinar Karaca-Mandic. "Association Between Regulatory Submission Characteristics and Recalls of Medical Devices Receiving 510(k) Clearance". JAMA 329, n.º 2 (10 de enero de 2023): 144. http://dx.doi.org/10.1001/jama.2022.22974.
Texto completoResumen
ImportanceMost regulated medical devices enter the US market via the 510(k) regulatory submission pathway, wherein manufacturers demonstrate that applicant devices are “substantially equivalent” to 1 or more “predicate” devices (legally marketed medical devices with similar intended use). Most recalled medical devices are 510(k) devices.ObjectiveTo examine the association between characteristics of predicate medical devices and recall probability for 510(k) devices.Design, Setting, and ParticipantsIn this exploratory cross-sectional analysis of medical devices cleared by the US Food and Drug Administration (FDA) between 2003 and 2018 via the 510(k) regulatory submission pathway, linear probability models were used to examine associations between a 510(k) device’s recall status and characteristics of its predicate medical devices. Public documents for the 510(k) medical devices were collected using FDA databases. A text extraction algorithm was applied to identify predicate medical devices cited in 510(k) regulatory submissions. Algorithm-derived metadata were combined with 2003-2020 FDA recall data.ExposuresCitation of predicate medical devices with certain characteristics in 510(k) regulatory submissions, including the total number of predicate medical devices cited by the applicant device, the age of the predicate medical devices, the lack of similarity of the predicate medical devices to the applicant device, and the recall status of the predicate medical devices.Main Outcomes and MeasuresClass I or class II recall of a 510(k) medical device between its FDA regulatory clearance date and December 31, 2020.ResultsThe sample included 35 176 medical devices, of which 4007 (11.4%) were recalled. The applicant devices cited a mean of 2.6 predicate medical devices, with mean ages of 3.6 years and 7.4 years for the newest and oldest, respectively, predicate medical devices. Of the applicant devices, 93.9% cited predicate medical devices with no ongoing recalls, 4.3% cited predicate medical devices with 1 ongoing class I or class II recall, 1.0% cited predicate medical devices with 2 ongoing recalls, and 0.8% cited predicate medical devices with 3 or more ongoing recalls. Applicant devices citing predicate medical devices with 3 or more ongoing recalls were significantly associated with a 9.31–percentage-point increase (95% CI, 2.84-15.77 percentage points) in recall probability compared with devices without ongoing recalls of predicate medical devices, or an 81.2% increase in recall probability relative to the mean recall probability. A 1-SD increase in the total number of predicate medical devices cited by the applicant device was significantly associated with a 1.25–percentage-point increase (95% CI, 0.62-1.87 percentage points) in recall probability, or an 11.0% increase in recall probability relative to the mean recall probability. A 1-SD increase in the newest age of a predicate medical device was significantly associated with a 0.78–percentage-point decrease (95% CI, 1.29-0.30 percentage points) in recall probability, or a 6.8% decrease in recall probability relative to the mean recall probability.Conclusions and RelevanceThis exploratory cross-sectional study of 510(k) medical devices cleared by the FDA between 2003 and 2018 demonstrated significant associations between 510(k) submission characteristics and recalls of medical devices. Further research is needed to understand the implications of these associations.
26
Wang, Tao, Bai Qing Xiong, Ben Lin, Zheng Gen Hu y Xi Wu Li. "Exploration of Phase Dissolution during Solution Treatment for a New Al-3.86Cu-0.89Li-0.38Mg-0.28Ag Alloy". Materials Science Forum 1071 (18 de octubre de 2022): 30–37. http://dx.doi.org/10.4028/p-qn797y.
Texto completoResumen
The dissolution of the second phase during solution treatment was of great importance for achieving preferential properties via aging treatment for Aluminum-Lithium (Al-Li) alloys. The microstructure characteristics of an extruded Al-Li alloy and its second phase dissolution during solution treatment were studied, while related electrical conductivity and tensile properties after ageing were tested for verification. The results indicated that as the alloy solution was treated from 500°C to 520°C with a soaking time of 1.5h, the Cu-rich phase dissolved into the matrix continuously. The statistics of remained phase area fraction ascertained no obvious decrement from 510°C to 520°C and only Fe-containing phase with large size was detected. Meanwhile, tensile properties under the same aging regime declared a higher strength was obtained at 510°C. As the solution time varied from 0.5h to 5h at 510°C, the Cu-rich phase was detected in a soaking time of 0.5h while disappeared after 1.5h and only the Fe-containing phase was observed. Correspondingly, electrical conductivity exhibited a moderate growth while tensile strength obviously increased from 0.5h to 1.5h and then maintained a platform, which revealed a preferential solution regime of 510°C/1.5h. This gives a reference for the second phase dissolution during solution treatments and furtherly obtaining preferential solution regimes.
27
Kekan, M., J. Fiveash, J. M. Markert, G. Y. Gillespie, H. Kuo, S. Meleth, C. L. Gladson y L. B. Nabors. "A phase I study of ABT 510 and concurrent temozolamide and radiotherapy for patients with newly diagnosed glioblastoma multiforme". Journal of Clinical Oncology 27, n.º 15_suppl (20 de mayo de 2009): 2023. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.2023.
Texto completoResumen
2023 Background: ABT-510 (Abbott Laboratories, Abbott Park, IL, USA) is a Thrombospondin-1 (TSP-1) mimetic drug with anti-angiogenic properties. This phase I dose escalation trial was designed to study the maximum tolerated dose (MTD) of ABT 510 when used concurrently with temozolomide (TMZ) and radiotherapy (RT) in patients with newly diagnosed glioblastoma multiforme (GBM). Methods: A total of 23 patients with newly diagnosed, histologically verified GBM were enrolled between April 2005 and January 2007, after obtaining written consent. The study was approved by the University of Alabama at Birmingham (UAB) Institutional Review Board. Four cohorts with three patients in each, receiving subcutaneous ABT 510 injection at doses of 20, 50, 100, and 200 mg/day were studied. The starting dose was primarily based on preclinical findings from animal studies and phase I studies on healthy subjects and cancer patients. Treatment plan included 10 weeks of induction phase (TMZ and RT with ABT 510) followed by a maintenance phase (ABT 510 and TMZ) of 14 cycles each consisting of 28 days. Patients were monitored with brain MRI along with laboratory values for dose limiting toxicities (DLT) defined as grades 3–4 non-hematological toxicities and grade 4 hematological toxicities (neutropenia or thrombocytopenia). In the absence of a DLT in at least two of the three patients, the dose was increased by 50% in the next cohort of patients. Therapy was discontinued if 14 maintenance cycles were completed, disease progression occurred, or if the patient requested withdrawal. Disease progression and survival statistics were analyzed. Results: During this trial, grade 3/4 DLT were not observed even after the dose was increased to 200 mg/day, hence, the last cohort was expanded to include 14 patients. A MTD was not defined. The median time to tumor progression (TTP) was 220 days and the median overall survival was 422 days. Gene expression analysis of the tumor pathology will be performed to evaluate the relationship between the expression of TSP-1, TSP-2, and patient response to the drug. Conclusions: ABT 510, at subcutaneous doses up to 200 mg/day, is tolerated well with concurrent TMZ and RT in patients with newly diagnosed GBM. No significant financial relationships to disclose.
28
Pant Pai, Nitika, Jana Daher, HR Prashanth, Achal Shetty, Rani Diana Sahni, Rajesh Kannangai, Priya Abraham y Rita Isaac. "Will an innovative connected AideSmart! app-based multiplex, point-of-care screening strategy for HIV and related coinfections affect timely quality antenatal screening of rural Indian women? Results from a cross-sectional study in India". Sexually Transmitted Infections 95, n.º 2 (15 de octubre de 2018): 133–39. http://dx.doi.org/10.1136/sextrans-2017-053491.
Texto completoResumen
ObjectivesIn rural pregnant Indian women, multiple missed antenatal screening opportunities due to inadequate public health facility-based screening result in undiagnosed HIV and sexually transmitted bloodborne infections (STBBIs) and conditions (anaemia). Untreated infections complicate pregnancy management, precipitate adverse outcomes and risk mother-to-child transmission. Additionally, a shortage of trained doctors, rural women’s preference for home delivery and health illiteracy affect health service delivery. To address these issues, we developed AideSmart!, an innovative, app-based, cloud-connected, rapid screening strategy that offers multiplex screening for STBBIs and anaemia at the point of care. It offers connectivity, integration, expedited communications and linkages to clinical care throughout pregnancy.MethodsIn a cross-sectional study, we evaluated the AideSmart! strategy for feasibility, acceptability, preference and impact. We trained 15 healthcare professionals (HCPs) to offer the AideSmart! strategy to 510 pregnant women presenting for care to outreach rural service units of Christian Medical College, Vellore, India.ResultsWith the AideSmart! screening strategy, we recorded an acceptability of 100% (510/510), feasibility (completion rate) of 91.6% (466/510) and preference of 73%. We detected 239 infections/conditions (239/510, 46.8%) at the point-of-care, of which 168 (168/239; 70%) were lab confirmed, staged and treated rapidly. Of the 168 confirmed infections/conditions, 127 were anaemia, 11 Trichomonas and 30 hepatitis B virus (HBV) (25 resolved naturally, 5 active infections). Four infants (4/5; 80%) were prophylaxed for HBV and were declared disease-free at 9 months. Recruited participants were young; mean age was 24 years (range: 17–40) and 74% (376/510) were in their second trimester. Furthermore, 95% of the participants were retained throughout their pregnancy.ConclusionThe AideSmart! strategy was deemed feasible to operationalise by HCPs. It was accepted and preferred by participants, resulting in timely screening and treatment of HIV/STIs and anaemia, preventing mother-to-child transmission. The strategy could be reverse-innovated to any context to maximise its health impact.
29
Kim, Chung Seok, Jin Woo Jo y Hak Min Lee. "The Effect of Solution Heat Treatment on Incipient Melting of Al2Cu Intermetallic Phase in Lightweight Materials". Materials Science Forum 857 (mayo de 2016): 256–60. http://dx.doi.org/10.4028/www.scientific.net/msf.857.256.
Texto completoResumen
The effects of solution heat treatment of Al6Si2Cu aluminum alloy on incipient melting of θ-Al2Cu phase have been investigated. Solution heat treatments, in this study, are applied to improve of mechanical properties through a single-step solution heat treatment. The microstructure of as-cast specimen represents a typical dendrite structure having a secondary dendrite arm spacing of 37um. In addition to the Al matrix, a large amount of coarsen eutectic Si, θ-Al2Cu intermetallic phases and Fe-rich phases are identified. As the solution temperature increases, the Vickers's hardness increases up to 510°C and thereafter hardness decreases at the temperature of 520°C and 530°C. This hardness behavior may closely related with microstructural evolution such as solubility of alloying elements up to 510°C and also melting of θ-Al2Cu intermetallic phases over 510°C in this study. Consequentially, the optimal single-step solution heat treatment temperature should be 510°C to improve mechanical property.
30
SEITZ, MICHELE L. "Disposable Diapers vs the Environment". Pediatrics 89, n.º 3 (1 de marzo de 1992): 523. http://dx.doi.org/10.1542/peds.89.3.523.
Texto completoResumen
To the Editor.— In the August issue of Pediatrics, Sutton, Weitzman, and Howland published a commentary on disposable diapers and the environmental concerns raised by their use.1 They presented a very one-sided argument in favor of cloth diapers and used data from a 1987 article in Consumer Reports (1987;52:510-512) to support their position. The 1987 price they quoted for using cloth diapers with a laundering service was approximately $26 per month, while the quoted cost for disposables was $84 per month.
31
Levine, Alexandra M., Lee Schwartzberg, Sonali Smith, Robert Belt, Raymond Knight, Dawn Carlson, Richard Hippensteel y Brad Kahl. "A Phase 2 Study of the Thrombospondin-Mimetic Peptide ABT-510 in Patients with Refractory Lymphoma." Blood 106, n.º 11 (16 de noviembre de 2005): 1493. http://dx.doi.org/10.1182/blood.v106.11.1493.1493.
Texto completoResumen
Abstract ABT-510 is a potent nonapeptide that mimics the antiangiogenic activity of the endogenous protein, thrombospondin-1. Dogs with spontaneous lymphoma showed a response rate of 17% (4/23). In 2 phase 1 studies in patients with solid tumors, ABT-510 was tolerated at doses up to 260 mg per day. Doses ≥20 mg daily exceeded the pharmacokinetic target of 100 ng/mL for >3 hours. 67 patients with relapsed or refractory lymphoma were randomized to receive ABT-510 10 mg or 100 mg twice daily (BID) by subcutaneous injection. The 10 mg BID arm was discontinued after 15 patients were enrolled to consolidate recruitment to the higher dose. The primary endpoint was tumor response; secondary endpoints included progression-free survival (PFS) and overall survival. Tumor progression was evaluated every 8 weeks by the Cheson criteria; safety was evaluated every 4 weeks. 6 of the 67 patients remain on active therapy. Data are available for 56 patients (32M/24F); the median age is 63 years (range 22–87), and the baseline ECOG Performance Score for all patients ranges from 0–2. All patients were heavily pretreated, with a median of 5 prior treatments (range 1–11). There are 3 partial responses, all in the 100 mg dose group in non-Hodgkins lymphoma (NHL) patients. PFS data are as follows: Patient Group N 6-month PFS % (90 % CI) 12 month PFS % (90 % CI) All 56 41 (28, 53) 17 (3, 31) 10 mg BID 15 34 (11, 56) 0 100 mg BID 38 48 (33, 64) 24 (8, 41) Hodgkins 11 29 (3, 55) 0 NHL 45 44 (30, 58) 22 (4, 40) Aggressive 17 29 (9, 49) 0 Indolent 27 51 (33, 70) 36 (16, 56) The most frequent adverse events (AEs) were asthenia (39%), injection site reaction (39%), diarrhea (24%), and anorexia (20%). 19% of patients had Grade 3–4 AEs considered related to ABT-510: anemia (4), thrombocytopenia (2), asthenia, chest pain, hemorrhage, gastrointestinal hemorrhage, leukopenia, and hypercalcemia (1 each). Correlative analyses of circulating endothelial cell data are pending. Based on these preliminary data, ABT-510 appears well-tolerated with biological activity in heavily pretreated patients with lymphoma. Study of ABT-510 in combination with immunotherapy or standard chemotherapy is warranted.
32
Hoekstra, Ronald, Filip Y. F. L. de Vos, Ferry A. L. M. Eskens, Jourik A. Gietema, Ate van der Gaast, Harry J. M. Groen, Raymond A. Knight et al. "Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Thrombospondin-1–Mimetic Angiogenesis Inhibitor ABT-510 in Patients With Advanced Cancer". Journal of Clinical Oncology 23, n.º 22 (1 de agosto de 2005): 5188–97. http://dx.doi.org/10.1200/jco.2005.05.013.
Texto completoResumen
Purpose ABT-510 is an angiogenesis inhibitor derived from thrombospondin-1, a naturally occurring inhibitor of angiogenesis. We investigated ABT-510, which was administered subcutaneously in patients with advanced solid malignancies, to assess safety, pharmacokinetics, and serum markers of angiogenesis. Patients and Methods ABT-510 was administered subcutaneously as a continuous infusion (100 mg/24 h) and bolus injections (100, 200, and 260 mg once daily; 50 and 100 mg twice daily) in 28-day cycles. Results Thirty-nine patients received a total of 144 treatment cycles. Administration by continuous infusion was hampered by the onset of painful skin infiltrates at the injection site. In the bolus injection regimens, the most common toxicities observed were mild injection-site reactions and fatigue. Maximum-tolerated dose was not defined, but 260 mg was defined as the maximum clinically practical dose. ABT-510 pharmacokinetics were linear across the dosage ranges tested, and the potential therapeutic threshold (plasma concentrations > 100 ng/mL > 3 h/d) was achieved with all dose regimens. Median serum basic fibroblast growth factor (bFGF) levels decreased from 14.1 pg/mL (range, 0.5 to 77.7 pg/mL) at baseline to 3.2 pg/mL (range, 0.2 to 29.4 pg/mL) after 56 days of treatment (P = .003). No correlations with time on study or ABT-510 dose or exposure were observed for individual changes in bFGF. Stable disease lasting for six cycles or more was seen in six patients. Conclusion ABT-510 demonstrated a favorable toxicity profile and linear and time-independent pharmacokinetics with biologically relevant plasma concentrations. The significant number of patients with prolonged stable disease and the convenient method of dosing merit further studies with this angiogenesis inhibitor.
33
Baker, Laurence H., Eric K. Rowinsky, David Mendelson, Rod A. Humerickhouse, Raymond A. Knight, Jiang Qian, Robert A. Carr, Gary B. Gordon y George D. Demetri. "Randomized, Phase II Study of the Thrombospondin-1-Mimetic Angiogenesis Inhibitor ABT-510 in Patients With Advanced Soft Tissue Sarcoma". Journal of Clinical Oncology 26, n.º 34 (1 de diciembre de 2008): 5583–88. http://dx.doi.org/10.1200/jco.2008.17.4706.
Texto completoResumen
Purpose Sarcomas are among the most proangiogenic malignancies in preclinical models. Phase I study results for ABT-510, which inhibits angiogenesis via a novel thrombospondin-mimetic mechanism, suggested activity in soft tissue sarcoma (STS) patients. This phase II study further evaluated the safety and efficacy of ABT-510 in advanced STS patients. Patients and Methods Patients with metastatic or unresectable STS were randomly assigned to treatment with one of two ABT-510 dose schedules (20 mg once a day [20 mg], n = 42; or 100 mg twice a day [200 mg], n = 46), which were self-administered subcutaneously in 28-day treatment periods. End points included progression-free survival (PFS), objective response rate (ORR), overall survival (OS), and safety. Results Median PFS for the 20-mg arm was 94 days, with 4- and 6-month PFS rate estimates of 42% and 24%, respectively. Median PFS for the 200-mg arm was 64 days, with 4- and 6-month PFS rate estimates of 41% and 32%, respectively. Although only one objective response was noted, stable disease was observed in 52% (20 mg) and 48% (200 mg) of patients. Median OS was 431 days (20 mg) and 295 days (200 mg). ABT-510 was well tolerated. Rare treatment-related grade 3 or 4 adverse events were one event each of hypotension, deep vein thrombosis, and hypophosphatemia. ABT-510 pharmacokinetics were dose proportional, time independent, and consistent with those in previous studies. Conclusion ABT-510 had a favorable safety profile, and the rate of disease control and OS times were encouraging. However, with low ORR and lack of dose response, the study failed to yield compelling evidence of strong single-agent activity in STS.
34
Strauss-Riggs, Kandra, Kevin Yeskey, Aubrey Miller, Stacey Arnesen y Craig Goolsby. "Translating Battlefield Practices to Disaster Health". Disaster Medicine and Public Health Preparedness 11, n.º 4 (9 de febrero de 2017): 510–11. http://dx.doi.org/10.1017/dmp.2016.196.
Texto completoResumen
AbstractWe review aspects of the recently released National Academies of Sciences, Engineering, and Medicine report A National Trauma Care System: Integrating Military and Civilian Trauma Systems to Achieve Zero Preventable Deaths After Injury most relevant to disaster health, particularly the concepts of focused empiricism and building a learning health system. The article references battlefield success utilizing these concepts and the emerging Disaster Research Response Program. We call upon disaster health researchers to apply the report’s recommendations to their work. (Disaster Med Public Health Preparedness. 2017;11:510–511)
35
Bulbul, Ajaz, Tareq Braik, Sadaf Rashad, Emilio Araujo Mino, Adrianna Bautista, Masoud Khorsand-Sahbaie y Debu Tripathy. "Trends in rates of modified radical mastectomies and bilateral mastectomies in unilateral breast cancer." Journal of Clinical Oncology 35, n.º 15_suppl (20 de mayo de 2017): 569. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.569.
Texto completoResumen
569 Background: Women with unilateral breast cancer (BC) without genetic predisposition have a low risk for local and contralateral recurrence with breast conservation surgery (BCS) and adjuvant treatment. We aimed to study the pattern of surgical care across centers in rural New Mexico and its correlation to clinical outcomes. Methods: We retrospectively evaluated 533 patients with Stage 1-3 BC diagnosed between January 1989 to October 2015. Clinical Outcomes with BCS, sentinel lymph node dissection (SLND), simple mastectomy (SM), modified radical mastectomy (MRM) and Bilateral Mastectomy (BM) were studied. Descriptive statistics were performed to describe the proportion of surgery types. Predictors of clinical outcomes were evaluated by multivariate logistic regression. Results: Out of 533 patients, 510 (82%) had early stage (0-3) resectable BC. Among these, 48% (246/510) had either MRM (209/510) or BM (37/510). MRM was performed in 3% of stage 0 (6/209), 23% (49/209) stage I, 46%(97/209) of stage II and 27% (57/209) of Stage III patients. Overall, the rate of SLND was 42% among Early stage Breast cancer. Of 41 patients treated with bilateral mastectomy, 10 were positive for BRCA mutation, 6 for family history and 3 for contralateral disease. Median age of BM was 53 +12 y. The local recurrence rate was 8.8% (45/510), and metastatic recurrence rate was 15.5% (79/510). Lymphedema rate was 9.2% (47/510). Using MRM as reference, the Odds Ratio (OR) for lymphedema after BM and BCT were 2.15 (95% CI, 0.84-5.50) and 0.58 (0.28-1.22), respectively. With 9.6 years of median follow up, the predictive probabilities of lymphedema after BCT, SM, MRM and BM were 1%, 4%, 9% and 18%. The OR for local recurrence in women with BCT were 1.46 (95th C/I: 0.72-2.95), SM 0.27 (0.03-2.13), BM 2.06 (95th C/I:0.70-6.06). Conclusions: Less BCT and more aggressive procedures are being performed, and the latter is associated with more lymphedema. No significant differences were noted in local recurrences. Presence of a genetic mutation was not the sole indicator of BM’s in our patient population. There is a need for evidence-based shared decision-making and surgical management of breast cancer, especially in a rural community setting.
36
Binh Minh, Phan Xuan, Bui Thi Thanh Phuong, Pham Huong Son, Tran Minh Hoi, Nguyen Thi Phuong Lan y Vu Thi Thao. "The effects of linght emitting diode lighting on growth and development of A. annanesis and A. roxburghii in vitro cultured shoots". TAP CHI SINH HOC 40, n.º 1 (6 de diciembre de 2017): 32–38. http://dx.doi.org/10.15625/0866-7160/v40n1.10636.
Texto completoResumen
A. annamensis and A. roxburghii belong to Orchidaceae family that has medicinal and ornamental plant value. They are in extinct endangered plants in wild due to the over- collected and loss of the suitable habitats. Using the LED lighting source for culture these species in in vitro condition to optimize the culture conditions, reduction of the production cost, especially electric bill for air-corditionning, lighting. In recent years, the trial applied LED which has the feature of energy saving, small size and a longer operating life, for plant production has started. In this study, LED illumination sources are in four different wavelengths of λ= 430- 470 nm; λ= 470-510 nm; λ= 510-560 nm; λ= 560-600 nm and white fluorescent lamp as control with light intensity photosynthetic photon flux density (PPFD) of 40 µmol/m2/s photon used to study their effects on the growth and development of A. annamensis and A. roxburghii species. After 8 weeks of implementing, the results showed that the LEDs of λ= 470-510 nm were suitable for the growth and development for A. roxburghii shoots while for A. annamensis, λ = 430- 470 nm were most suitable for budding and λ= 470-510 nm for shoot growth. Citation: Phan Xuan Binh Minh, Bui Thi Thanh Phuong, Pham Huong Son, Tran Minh Hoi, Nguyen Thi Phuong Lan, Vu Thi Thao, 2018. The effects of linght emitting diode lighting on growth and development of A. annanesis and A. roxburghii in vitro cultured shoots. Tap chi Sinh hoc, 40(1): x-xx. DOI: 10.15625/0866-7160/v40n1.10636. *Corresponding author: pxbminh@gmail.com Received 23 August 2017, accepted 2 December 2017
37
Peters, Wesley, Carl Pellerin y Cory Janney. "RESEARCH: Evaluation of Orthopedic Hip Device Recalls by the FDA from 2007 to 2017". Biomedical Instrumentation & Technology 54, n.º 6 (1 de noviembre de 2020): 418–26. http://dx.doi.org/10.2345/0899-8205-54.6.418.
Texto completoResumen
Background: Medical device recalls have increased in the previous two decades. Orthopedic devices are estimated to constitute 12% of all medical devices recalled. Medical devices enter the market via the Food and Drug Administration's (FDA's) premarket approval (PMA) or 510(k) pathways. This article evaluates orthopedic hip device recalls between Jan. 1, 2007, and Dec. 31, 2017. We hypothesized that the 510(k) approval process would have substantially higher recall rates for defective devices. Methods: The FDA's device recall database was queried for all orthopedic hip devices from Jan. 1, 2007, to Dec. 31, 2017. Each recall included product description, recall number, device class, date of recall posting, date of recall termination, manufacturer, FDA-determined cause for recall, number of recalled units, distribution, product classification, and method of approval [510(k), PMA, or unspecified]. Results: In total, 774 orthopedic hip devices were recalled between Jan. 1, 2007, and Dec. 31, 2017. The 510(k) approval process constituted 85% of hip device recalls. The most common FDA-determined cause of hip device recalls was device design, which constituted 37% of 510(k)-approved device recalls but only 6% of PMA-approved device recalls. The most recalled hip devices were hip prostheses. Orthopedic hip device recalls have shown a decrease of about 10 recalls per year during the 11-year period of analysis. Conclusion: Devices approved through the 510(k) process, compared with the PMA process, were more likely to be recalled for design defects. Although device design is the most common reason for device recall, many recalls are due to suboptimally standardized processes (e.g., packaging, process controls, device labeling). Overall, orthopedic hip device recalls decreased during the period of analysis (2007–17).
38
Yaccoby, Shmuel, Wen Ling, Rinku Saha, Kenichiro Yata y Guido Tricot. "Systemic Treatment with the Antiangiogenic Agent ABT-510 Inhibited Myeloma-Induced Microvessels and Tumor Growth in Myelomatous SCID-hu Mice." Blood 106, n.º 11 (16 de noviembre de 2005): 3451. http://dx.doi.org/10.1182/blood.v106.11.3451.3451.
Texto completoResumen
Abstract Myeloma cells induce bone marrow angiogenesis and increased microvessel density (MVD) is associated with poor prognosis in this disease. The aim of this study was to investigate whether neovascularization is required for myeloma growth by testing the anti-angiogenesis and anti-tumor efficacy of thrombospondin-1 (TSP-1)-derived mimetic peptide, ABT-510 (Abbott Laboratories), in the SCID-hu model for primary myeloma. TSP-1 is a matricellular glycoprotein with multiple biological functions, including antiangiogenic activity. ABT-510 is a capped nonapeptide based on the linear TSP-1 heptapeptide sequence. Like TSP-1, ABT-510 can be targeted to a specific receptor on vascular endothelial cells and efficiently inhibits angiogenesis in vitro and after systemic injection in experimental models of human malignancies. SCID-hu mice were constructed as previously described (Yaccoby et al., Blood 1998; 1999; 2002). Myelomatous SCID-hu mice were prepared by injection of myeloma cells from 6 patients into the implanted human bone in the hosts. Changes in levels of tumor burden were monitored by weekly measurements of human monotypic immunoglobulins (hIg) using ELISA and histologically confirmed by immunohistochemical staining of human bone sections for cIg. MVD, visualized by CD34 staining, were counted in 4 non-overlapping areas. Upon establishment of myeloma growth (401±146 μg/ml pre-treatment levels) mice were intraperitoneally injected with ABT-510 (100 mg/kg, twice a day) or with the vehicle (5% dextrose) for 4–10 weeks. Treatment was well tolerated and no sign of toxicity or reductions in body weight were observed. Whereas all dextrose -treated mice had increased hIg levels during the experimental period, ABT-510 treatment resulted in marked reduction of tumor burden in 2 experiments by 48% and 20%, respectively, retardation of myeloma growth in 3 additional experiments and no response in one experiment. Overall, tumor burden in control- and ABT-510-treated mice was increased by 3696%±3264 and 448%±169 from pre-treatment levels, respectively (p<0.03). MVD in control- and ABT-510-treated mice were 21±6/mm2 and 11±4/mm2, respectively (p<0.02). Intriguingly, MVD in the non-responding mouse was reduced by >35% (11±2 vs. 17±1 microvessels/MM2 in control mouse, p<0.04), suggesting that certain myeloma cells are not dependent on neovascularization. We conclude that myeloma cells from the majority of patients require angiogenesis for growth and that ABT-510, which is undergoing a phase II clinical trial for treating solid tumors, is a potential agent for treating myeloma.
39
Chen, Bolin, Shuzhi Liang, Haibin Guo, Li Xu, Jia Li y Jie Peng. "OPN Promotes Cell Proliferation and Invasion through NF-κB in Human Esophageal Squamous Cell Carcinoma". Genetics Research 2022 (15 de diciembre de 2022): 1–8. http://dx.doi.org/10.1155/2022/3154827.
Texto completoResumen
Background. Osteopontin (OPN) is a phosphorylated glycoprotein. There is increasing evidence that the OPN gene played a major role in the progression of solid organ tumors. However, few studies have clarified how OPN regulated the functional role of human esophageal squamous cell carcinoma (ESCC). This study was designed to investigate the effect of OPN in esophageal squamous cell carcinoma. Methods. First, we screened Eca-109 and KYSE-510 cells to construct OPN silencing and overexpression models. Endogenous OPN of Eca-109 and KYSE-510 were knocked down or overexpressed using small interfering RNAs. QRT-PCR, Western blot, flow cytometry, and CCK-8 were used to detect the function of Eca-109 and KYSE-510 cells. Tumor formation in nude mice was used to measure tumor growth after OPN inhibition. Results. Eca-109 and KYSE-510 cells contain the si-OPN arrest cell cycle in the S-phase and increase apoptosis. These changes were OPN downregulation of the NF-κB pathway that significantly reduced the protein levels of TNF-α, IL-1β, and p-p65. However, the activity of Eca-109 and KYSE-510 cells was enhanced in OPN overexpressing cells. Then, the in vivo tumor formation experiment in nude mice showed that the tumor volume and weight of nude mice after silencing OPN were significantly reduced. Conclusion. This study contributed to understanding the vital role of OPN in ESCC development and progression. This could be a promising molecular target for developing new ESCC diagnostic and therapeutic strategies.
40
Hojat, Leila, David Kaelber y Ann Avery. "Population-Level Hepatitis C Testing Using A Personal Electronic Health Portal System Significantly Improves Screening Rates in Baby Boomers". Open Forum Infectious Diseases 4, suppl_1 (2017): S329. http://dx.doi.org/10.1093/ofid/ofx163.779.
Texto completoResumen
Abstract Background Hepatitis C virus (HCV) infection is a major public health burden. The USPSTF and CDC have both released guidelines which recommend screening the baby boomer population (individuals born between 1945 and 1965) given the overrepresentation of HCV infection in this cohort. However, screening rates remain low despite prior attempts at improvement. Objective To improve HCV testing rate in the birth cohort in compliance with national guidelines without increasing primary care provider workload or alert fatigue. Methods We developed a population health initiative that employed EHR-based tools involving direct patient messaging and bulk lab test ordering via a personal electronic health portal system. This was completed independent of a face-to-face interaction between the patient and provider. Results We collected data on 1,024 patients total (514 in the intervention group and 510 in the control group) over a 12-week period. We found a statistically significant higher test completion rate within the intervention group vs. the control group after this initiative was launched: 33.7% in the intervention group (173/514) vs. 19.0% in the control group (97/510) (p-value <0.0002, OR 2.16, 95% CI 1.62–2.88). Bulk lab ordering appeared to have a large impact while bulk messaging appeared to have a less significant role. Conclusion To our knowledge, this is the first EHR-based population health initiative to involve obtaining blood work without a direct face-to-face encounter between the provider and patient. This methodology has a broad range of applications including any recommended screening or disease-specific testing, and it will be essential for health systems to adopt similar protocols as we progress toward a pay-for-performance reimbursement model. Disclosures All authors: No reported disclosures.
41
Pffeifer, Ernesto. "Revista Atenea Nº 510, número de Homenaje a Nicanor Parra". Revista chilena de literatura, n.º 91 (noviembre de 2015): 186–88. http://dx.doi.org/10.4067/s0718-22952015000300014.
Texto completo
42
TAKAMATSU, Ayumi, Jyo SHIMURA y Shigeru KUROSAKI. "510 A Trial on Defect Detection using Piezoelectric Polymer Film". Proceedings of Yamanashi District Conference 2013 (2013): 130–31. http://dx.doi.org/10.1299/jsmeyamanashi.2013.130.
Texto completo
43
Negishi, Shigetoshi y Yoshihiro Yanamoto. "510 Several Problems Concerning Engineering Education of A Small Company". Proceedings of Conference of Kansai Branch 2007.82 (2007): _5–12_. http://dx.doi.org/10.1299/jsmekansai.2007.82._5-12_.
Texto completo
44
Sartorius, N. "510 – Future directions for European psychiatry - A 30 year perspective". European Psychiatry 28 (enero de 2013): 1. http://dx.doi.org/10.1016/s0924-9338(13)75817-6.
Texto completo
45
Weber, Richard W., T. Ray Vaughan y William K. Dolen. "510 A ten year review of adverse reactions to immunotherapy". Journal of Allergy and Clinical Immunology 81, n.º 1 (enero de 1988): 295. http://dx.doi.org/10.1016/0091-6749(88)90744-0.
Texto completo
46
Hasheminiya, Tahere, Mohammadreza Saberiyan, Delnya Gholami y Hossein Teimori. "miR-508-5p and mir-510-5p expressions and their relationships with spermatozoa motility and morphology". Journal of Shahrekord University of Medical Sciences 22, n.º 3 (29 de junio de 2020): 146–50. http://dx.doi.org/10.34172/jsums.2020.23.
Texto completoResumen
Background and aims:miRNAs have regulatory functions in developmental processes. The stages of spermatogenesis can also be affected by miRNAs. We tried to detect a relationship between the expression of miR-508-5p and miR-510-5p and male infertility. The purpose of this study was to investigate the association between expression of miR-508-5p and mir-510-5p in ejaculated sperm from patients with idiopathic asthenozoospermia, teratozoospermia, and teratoasthenozoospermia. Materials and Methods:We enrolled 18 men with asthenozoospermia, 17 men with teratozoospermia, 18 men with teratoasthenozoospermia, and 18 individuals with normozoospermia based on the clinical criteria. Then, the expressions of the mentioned miRs in the spermatozoa were evaluated by quantitative real-time PCR (qRT-PCR). Kruskal-Wallis was used to compare their expressions in the studied groups. Results: The expression of mir-508-5p did not show any statistical significance in all groups. On the other hand, the expression of miR-510- 5p in teratozoospermia groups (P<0.05) and the asthenozoospermia group (P<0.05) demonstrated a significant downregulation compared with the control and teratoasthenozoospermia groups. Conclusion: By analyzing the expression profile of miRNAs, we concluded that the expression level of miR-510-5p changed in patients with abnormal motility and morphology of spermatozoa; therefore, it may affect infertility by down-regulating the expression of mir-510-5p which shows the role of it in abnormal morphology and motility defects in infertility cases.
47
Pewe, Lecia, Stephen B. Heard, Conni Bergmann, Morris O. Dailey y Stanley Perlman. "Selection of CTL Escape Mutants in Mice Infected with a Neurotropic Coronavirus: Quantitative Estimate of TCR Diversity in the Infected Central Nervous System". Journal of Immunology 163, n.º 11 (1 de diciembre de 1999): 6106–13. http://dx.doi.org/10.4049/jimmunol.163.11.6106.
Texto completoResumen
Abstract Variant viruses mutated in the immunodominant cytotoxic T cell epitope surface (S) glycoprotein S-510-518 are selected in mice chronically infected with mouse hepatitis virus, strain JHM. We determined whether this selection occurred in the presence of an oligoclonal or polyclonal T cell response using soluble MHC/peptide tetramers in direct ex vivo analyses of CNS-derived lymphocytes. A total of 42% (range, 29–60%) of CD8 T cells in the CNS of mice with acute encephalitis recognized epitope S-510-518. A total of 34% (range, 18–62%) of cells from mice with hind limb paralysis (and chronic demyelination) were also epitope specific, even though only virus expressing mutated epitope is detected in these animals. Sequence analysis of the β-chain CDR3 of 487 tetramer S-510-518-positive cDNA clones from nine mice showed that a majority of clonotypes were identified in more than one mouse. From these analyses, we estimated that 300–500 different CD8 T cell clonotypes responsive to epitope S-510-518 were present in each acutely infected brain, while 100–900 were present in the CNS of each mouse with chronic disease. In conclusion, a polyclonal CD8 T cell response to an epitope does not preclude the selection of T cell escape mutants, and epitope-specific T cells are still present at high levels even after RNA-encoding wild-type sequence is no longer detectable.
48
Francisco, Deise Juliana y Luciana Santana. "Resolução 510/2016: reflexões desde a inserção em um Comitê de Ética em Pesquisa". Revista Mundaú, n.º 2 (12 de agosto de 2017): 67–79. http://dx.doi.org/10.28998/rm.2017.n.2.3315.
Texto completoResumen
Este artigo discute alguns aspectos da Resolução 510/2016 à luz da implicação da autora como membro de Comitê de Ética em Pesquisa. Apresenta reflexões sobre temas tais como consentimento livre e esclarecido e vulnerabilidade, problematizando a questão do anonimato do participante em alguns tipos de pesquisa. Conclui que a Resolução 510/2016 apresenta algumas especificidades das pesquisas no campo das Ciências Humanas e Sociais, contribuindo com a avaliação ética das pesquisas e ao respeito à diversidade metodológica das pesquisas, apesar de ainda não concretizar uma efetiva ruptura com a regulação e avaliação ética em pesquisa no Brasil.
49
Li, Han Sheng, Hang Xu, Shi Ying Wang, Ya Lin Pan, Qin Wu y Chang Hao Liu. "Preparation of Nano-TiO2 Using a Sol-Gel Process Mediated in Reverse Microemulsion Combined with a Solvent Thermal Technique". Advanced Materials Research 287-290 (julio de 2011): 1731–34. http://dx.doi.org/10.4028/www.scientific.net/amr.287-290.1731.
Texto completoResumen
Anatase nano-titania (nano-TiO2) was prepared by using a sol-gel process mediated in reverse microemulsion combined with a solvent thermal technique. The results show that the anatase structure appears in the calcination temperature range of 400-510°C, while the transformation of anatase into rutile takes place above 510°C. The average particle size (dP) of the nano-TiO2 increases with the rise of water/Triton X-100 molar ratio (ω) but decreases with the rise of acetyl acetone/n-TBT molar ratio (p) and n-hexanol/Triton X-100 molar ratio (m). The obtained TiO2 particles with a small size have high photocatalytic activity.
50
Onishi, S., S. Itoh y K. Isobe. "Wavelength-dependence of the relative rate constants for the main geometric and structural photoisomerization of bilirubin IX α bound to human serum albumin. Demonstration of green light at 510 nm as the most effective wavelength in photochemical changes from (ZZ)-bilirubin IX α to (EZ)-cyclobilirubin IX α via (EZ)-bilirubin". Biochemical Journal 236, n.º 1 (15 de mayo de 1986): 23–29. http://dx.doi.org/10.1042/bj2360023.
Texto completoResumen
The kinetics for the quantitatively important reaction: (Formula: see text) that is, the photochemical interconversion between bilirubin and its geometric and structural photoisomers bound to human serum albumin in aqueous solution when various wavelengths of monochromatic light were used, were assayed by h.p.l.c. In order to clarify the wavelength-dependence of the relative rate constants in the individual steps, a light-source with a half-bandwidth of 10 nm was used at increments of 20 nm, in the range from 410 nm to 550 nm. We describe for the first time studies on the wavelength-dependence of rate constants in geometric and structural photoisomerization reactions in vitro of (ZZ)-bilirubin or (EZ)-bilirubin bound to human serum albumin, especially the relative rate constants of cyclization of (EZ)-bilirubin into (EZ)-cyclobilirubin. Because studies in vitro have demonstrated that the wavelengths from 350 to 450 nm are mutagenic, the results obtained indicated that the safest and ideal light-source for phototherapy is green light of 510 nm, which keeps (ZE)-bilirubin concentrations as low as possible, as shown by a maximal value of k2 at 510 nm and a relatively low value of k1 at 510 nm. This light-source still ensures the substantial absorption of (ZZ)-bilirubin, which is the precursor of (EZ)-bilirubin, the intermediate in (EZ)-cyclobilirubin formation and, furthermore, as shown by the maximal value of k5 and a considerable value of k4 at 510 nm, promotes the cyclization of (EZ)-bilirubin derived from (ZZ)-bilirubin even though k3 at 510 nm also shows a peak value.